INTRODUCTION
Status epilepticus (SE) is a medical and neurologic emergency. Overall, mortality is approximately 17% to 26% (Claassen et al, 2002b; DeLorenzo et al, 1996; Logroscino et al, 2001 ). An additional 10% to 23% of patients who survive SE are left with new or disabling neurologic deficits (Claassen et al, 2002b; Lowenstein and Alldredge, 1998) . This significant risk of death or permanent neurologic injury is mediated through multiple mechanisms .
DEFINITION AND CLASSIFICATION Definition
Traditionally, SE is defined as continuous or repetitive seizure activity persisting for at least 30 minutes without recovery of consciousness between attacks. More recently, authors have suggested that seizures exceeding 5 to 11 minutes should be considered SE (Jenssen et al, 2006; Lowenstein et al, 1999) . For all practical purposes, a patient should be considered to be in SE if a seizure persists for more than 5 minutes, as very few single seizures will last this long.
Classification SE is typically classified into convulsive and nonconvulsive, based on whether or not rhythmic jerking of the extremities is observed. There is no clear consensus on further classification of nonconvulsive SE (NCSE). Many authors have classified NCSE into generalized or partial onset and simple or complex based on whether alteration of consciousness exists. In clinical practice, however, it is often not possible to differentiate between NCSE of generalized onset (also known as absence status or spike-and-wave stupor [Case 6-1]) and NCSE of partial onset with bilateral spread (complex partial SE), even with EEG. In the intensive care unit (ICU), most seizures are nonconvulsive and would be missed in the absence of continuous EEG monitoring (Cases 6-2 and 6-3) (Claassen et al, 2004) .
ETIOLOGY AND RISK FACTORS
The most frequent cause of SE is a prior history of epilepsy (22% to 26%). However, more than half of SE episodes occur in patients without prior seizures. In these patients, stroke (19% to 20%) is the most frequent cause, as in Case 6-2. Other etiologies are listed in Figure 6 -2.
DIAGNOSIS
Early recognition of SE allows for prompt treatment and increases the likelihood of treatment success and prevention of further neuronal damage. Typically, patients who present with generalized convulsive SE are expected to awaken gradually after the motor features of seizures disappear. If the level of consciousness is not improving by 20 minutes after cessation of movements, or the mental status remains abnormal 30 to 60 minutes after the convulsions cease, NCSE must be considered and urgent EEG is advised.
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FIGURE 6-1 Potential hazards of status epilepticus: potentially self-perpetuating mechanisms of injury. " = increased; K = potassium; Na = sodium.
A If the level of consciousness is not improving by 20 minutes after cessation of movements, or the mental status remains abnormal 30 to 60 minutes after the convulsions cease, nonconvulsive SE (NCSE) must be considered.
A NCSE has protean manifestations. Any fluctuating or unexplained alteration in behavior or mental status warrants an EEG and consideration of NCSE.
KEY POINTS:
A More than one half of episodes of SE occur in patients without prior seizures. In these patients, stroke is the most frequent cause (19% to 20%).
A Early recognition of SE allows for prompt treatment and increases the likelihood of treatment success and prevention of further neuronal damage.
Nonconvulsive Status Epilepticus: a Diagnosis Not to Be Missed NCSE is much more common than previously recognized, particularly in ICU patients. It is crucial to recognize and treat NCSE early, since prognosis worsens with increasing duration of seizure activity (Young et al, 1996) . The varied presentation of NCSE can lead to misdiagnosis or delayed treatment. Table 6 -1 lists possible presentations of NCSE. As a general rule, any fluctuating or unexplained alteration in behavior or mental status warrants an EEG and consideration of NCSE (Case 6-1). See Table 6 -2 for the criteria for diagnosing nonconvulsive seizures. A suggested method for performing a benzodiazepine trial to diagnose NCSE is presented in Table  6 -3. A common error is to give too high a dose of benzodiazepine, resulting in marked sedation, which has no diagnostic utility even if the EEG pattern rapidly resolves. Small incremental doses may allow observation of a clinical improvement without marked sedation.
Risk Factors for Nonconvulsive Status Epilepticus
Although all the clinical presentations listed in Table 6 -1 can represent NCSE, studies (primarily in the critically ill) have found that the diagnosis is particularly likely in children and in those with severely impaired mental status, a history of epilepsy or remote epilepsy risk factors, convulsive Case 6-2
A 67-year-old man with hypertension and atrial fibrillation who has been taking warfarin presents with dizziness, left hemiparesis, and lethargy. Initial head CT is negative and international normalized ratio is subtherapeutic. In the emergency department, the neurology consultant notes rhythmic facial twitching, and the patient is loaded with fosphenytoin 18 mg/kg. No further twitching is seen, and initial overnight EEG shows right hemisphere slowing and occasional isolated epileptiform discharges on the right, but no seizures. Fosphenytoin is discontinued after several days, and levetiracetam is started instead to minimize drug interactions and potential long-term adverse effects. Repeat head CT shows hemorrhagic conversion of a moderate to large right middle cerebral artery infarct 
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Copyright @ American Academy of Neurology. Unauthorized reproduction of this article is prohibited. and a smaller left medial parietal hemorrhagic infarct. The patient is stable but develops medical complications, including pneumonia, renal insufficiency, and a deep vein thrombosis. On day 14 of his hospital stay, he has a witnessed convulsion followed by continued impaired mental status and leg twitching. He is given 4 mg of lorazepam and is reloaded with fosphenytoin 18 mg/kg. All motor activity ceases after about 15 minutes, as fosphenytoin is being administered. Urgent EEG is arranged and shows nearly continuous seizures from the left posterior quadrant (Figures 6-6 through 6-8) lasting up to 4 minutes each with only a minute or so between seizures. There is no clinical correlate to any of these electrographic seizures.
Levetiracetam is increased to 1500 mg 2 times per day, and phenytoin is given 100 mg 3 times per day via feeding tube. However, levels are low and erratic with enteric administration so fosphenytoin is resumed IV at 200 mg 2 times per day instead, maintaining total phenytoin serum levels at approximately 8 g/mL to 12 g/mL, which corresponds to a measured free phenytoin level of 2.0 g/mL to 3.0 g/mL. Seizures rapidly decrease to a few isolated nonconvulsive seizures per day that resolve over a few days as his medical condition improves and phenytoin levels are maximized. Because the patient is occasionally agitated, levetiracetam is changed to gabapentin, which is rapidly increased to 900 mg 3 times per day. His mental status improves gradually. He resumes speaking and following simple commands, but he is left with significant neurologic impairment. He is discharged to a nursing home.
Comment. This case shows NCSE after an isolated but prolonged convulsive seizure in an acutely ill inpatient in the poststroke setting. Medication management was complicated by the desire to avoid drug interactions in a complex medical patient (by avoiding the strong P450 enzyme-inducer phenytoin), probable poor gastrointestinal absorption (preventing confidence in enteral medications, especially ones without readily available serum levels), and agitation (which can occur from some antiepileptic medications, particularly levetiracetam). EEG monitoring played an important role in following his nonconvulsive seizures, as they Continued from page 125 continued on page 127 " STATUS EPILEPTICUS seizures prior to the EEG, and ocular movement abnormalities (sustained eye deviation, nystagmus or hippus) (Claassen et al, 2004; Husain et al, 2003) . In our series of 570 consecutive inpatients (mostly in ICUs) undergoing continuous EEG monioring (Claassen et al, 2004) , 110 (19%) had seizures, and 101 of these 110 patients (92%) had purely nonconvulsive seizures that could only be detected by EEG. Only one half of these patients had their first seizure within the first hour of recording; thus, even a prolonged routine EEG would not have identified the nonconvulsive seizures in half the patients. We concluded that 24 hours was a reasonable screen for nonconvulsive seizures in noncomatose patients, but that 48 hours or more may be needed in comatose patients. Periodic discharges were also associated with nonconvulsive seizures.
TREATMENT Rapidity of treatment is important in the treatment of SE. Animal and human data support the concept that pharmacologic therapeutic interventions are most effective when initiated early, and that efficacy decreases significantly with increasing seizure duration (Lowenstein and Alldredge, 1993; Mazarati et al, 1998) . For practical purposes, treatment should be started after 5 minutes of continuous seizure activity.
Initial Management
We find use and wide distribution of a written protocol for treatment of SE 127 could not otherwise be identified. Seizures increase metabolic demand and cerebral blood flow and release glutamate, all of which are likely to exacerbate neuronal injury in the acute stroke setting. As is typical in critically ill patients, the occasional clinical seizure was just the tip of the iceberg. It is interesting that his seizures seemed to arise from the smaller left parietal hemorrhagic infarct rather than the large one on the right.
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FIGURE 6-8 End of seizure, 1 minute after EEG 2. After seizure offset, seizure activity is replaced by periodic lateralized epileptiform discharges recurring at just under 1 per second, also maximal in the left posterior quadrant.
Case 6-3
A 63-year-old healthy woman presents with viral symptoms, including fever, for a few days. She then has a convulsion. She is loaded with fosphenytoin in the emergency department, but her mental status remains impaired and intermittent focal seizures continue, consisting of eye deviation and facial twitching. Lorazepam is given several times. Lumbar puncture shows 13 to 22 white blood cells (mostly lymphocytes), mildly elevated protein, and normal glucose. Brain MRI is normal, as are all blood tests. CSF herpes simplex virus PCR and other encephalitis tests are negative. EEG monitoring shows NCSE . She is treated with many agents, including ceftriaxone, acyclovir, midazolam infusion, propofol infusion (following creatine phosphokinase, pH, and triglycerides), IV valproate, levetiracetam, topiramate (after propofol has been discontinued), oxcarbazepine (while following sodium closely), and prolonged pentobarbital coma for 4 weeks. Every 1 to 4 days, an attempt to wean her off of pentobarbital is attempted, but seizures recur each time for several weeks. Phenobarbital is maintained to attempt to minimize withdrawal seizures as pentobarbital is tapered, and this is eventually successful after the patient has been in iatrogenic coma for over 1 month. No organism is ever identified for her presumed encephalitis.
She gradually awakens. Intermittent isolated seizures are tolerated. Over the subsequent 2 months, she gradually returns to baseline mental status except for mild to moderate memory dysfunction. Subsequent MRIs show mild bilateral hippocampal atrophy and increased signal suggesting hippocampal sclerosis. She returns to work part time and functions well. One year later, she undergoes epilepsy monitoring for refractory seizures, averaging two per week. Bilateral independent temporal lobe seizures are identified as well as occipital simple partial seizures. She receives a vagus nerve stimulator, which helps modestly. She retires and now travels the world with her husband. " STATUS EPILEPTICUS quite helpful. A sample protocol (as used in our center) is given in Table  6 -4. Initial steps in the management of SE involve basic life support: administering oxygen, checking vital signs, and assessing and maintaining the airway. IV access should be established quickly, but rectal, buccal, or nasal benzodiazepines should be given if any delay will occur in obtaining IV access (see following section on alternative modes of administration). Laboratory studies should be ordered (Table 6-4). A fingerstick blood glucose level should be obtained, and 100 mg of thiamine and 50 mL of 50% glucose should be administered if glucose level is low or unknown. For seizures due to a metabolic abnormality, correcting the metabolic problem is more effective than administering antiepileptic drugs (AEDs). Fever, hypoxia, and hypotension should also be treated concurrently as these can exacerbate seizures and the associated neuronal injury.
Other components of management include determining whether there is a history of alcohol or drug use, previous epilepsy, or possible acute neurologic insult; obtaining a description of the seizure at onset if it was witnessed; and brain imaging once the patient is stable and seizures are controlled. Patients should not be pharmacologically paralyzed unless continuous EEG is being (1) Repetitive generalized or focal spikes, sharp waves, spike-and-slow-wave or sharp-and-slow-wave complexes at !3/s.
(2) Repetitive generalized or focal spikes, sharp waves, spike-and-slow-wave or sharp-and-slow-wave complexes at <3/s and the secondary criterion.
(3) Sequential rhythmic, periodic, or quasi-periodic waves at !1/s and unequivocal evolution in frequency (gradually increasing or decreasing by at least 1/s, eg, 2/s to 3/s), morphology, or location (gradual spread into or out of a region involving at least two electrodes). Evolution in amplitude alone is not sufficient. Change in sharpness without other change in morphology is not enough to satisfy evolution in morphology.
Secondary criterion:
Significant improvement in clinical state or appearance of previously absent normal EEG patterns (such as posterior dominant ''alpha'' rhythm) temporally coupled to acute administration of a rapidly acting antiepileptic drug. Resolution of the ''epileptiform'' discharges leaving diffuse slowing without clinical improvement and without appearance of previously absent normal EEG patterns would not satisfy the secondary criterion.
a Satisfying these criteria is adequate for confirming nonconvulsive seizure activity. However, failing to meet these criteria does not rule out nonconvulsive seizure activity; clinical judgment and correlation are required in this situation. b Periodic discharges are typically slower than three per second, falling under primary criterion 2 or 3; the secondary criterion hence becomes useful to differentiate ictal from nonictal. The cutoff of three per second seen within the primary criteria is at least partly in recognition of the epileptic encephalopathies, such as the Lennox-Gastaut syndrome, where nearly continuous repetitive spike-wave discharges occur, but those below three per second (''slow spike and wave'') are typically considered interictal rather than ictal (Young GB, personal communication 2005) . Periodic discharges with significant evolution in periodicity and amplitude would fall under primary criterion 3. For a detailed discussion of the basis of these criteria, see references below (Chong and Hirsch 2005; Young et al, 1996) . , 1993) . Benzodiazepines, potent, parentally available medications with a rapid onset of action, are the preferred initial therapy. Their mechanism of action involves binding to high affinity sites on the -aminobutyric acid receptor, resulting in hyperpolarization of the neuronal cell membrane and decreased neuronal firing (McDonald and McLean, 1986) . Most experts recommend IV lorazepam (0.1 mg/kg) as the first-line therapy. Patients who respond to firstline agents will usually require maintenance therapy with a second-line agent. Additional treatment must be provided quickly when patients continue to experience seizures. The longer SE persists, the higher the risk for developing refractory SE. Prospective data for second-line agents are lacking, but phenytoin or fosphenytoin is used most frequently (Claassen et al, 2003) .
Comparison of initial treatment options for status epilepticus. Only a few prospective randomized trials have been conducted comparing treatment strategies for SE. The largest was the Veterans Affairs Status Epilepticus Cooperative Study (Treiman et al, 1998) , which was a randomized, double-blind, multicenter trial that compared four IV treatments: lorazepam 0.1 mg/kg, diazepam 0.15 mg/kg plus phenytoin 18.0 mg/kg, phenobarbital 15.0 mg/kg, and phenytoin 18.0 mg/kg alone. In generalized convulsive SE, lorazepam was found to be most effective (65% for lorazepam alone versus 58% for (2006) randomly assigned 68 patients with convulsive SE to IV VPA (30 mg/kg) or phenytoin (18 mg/kg); seizures were aborted in 66% in the VPA group versus 42% in the phenytoin group. If the first agent failed, patients were given the other agent. As the second agent, VPA was effective in 79% and phenytoin was effective in 25%. Tolerability between the two groups did not differ (Misra et al, 2006) . Several other case series suggest good efficacy for IV VPA in the treatment of different types of SE, including partial onset, nonconvulsive, absence, and myoclonic status (Limdi et al, 2005; Peters and Pohlmann-Eden, 2005; Sinha and Naritoku, 2000) .
Phenytoin or fosphenytoin is the most frequently recommended second-line agent. Once patients fail to respond to two AEDs, seizure activity is often very difficult to control. In the Veterans Affairs Cooperative Study (Treiman et al, 1998) , of the 38% of patients with ''overt'' SE and the 82% of patients with ''subtle'' SE who continued to seize after receiving two AEDs, only 2% and 5% respectively stopped seizing after receiving a third agent. Even more disappointing was the fact that once lorazepam failed, very few patients responded to phenytoin as a secondline agent (approximately 5%); for this reason, some experts advocate progressing directly to continuous IV anesthetic drips once lorazepam has failed (Tables 6-4, 6-6G and 6-6H).
Use of adjunctive medications via nasogastric tube. AEDs that are only available in an oral form can be given via nasogastric tube or percutaneous endoscopic gastrostomy in patients with SE, although not for initial treatment. Levetiracetam (Rossetti et al, 2005) , topiramate (Towne et al, 2003) , gabapentin, oxcarbazepine, carbamazepine, and pregabalin have been used for this purpose, particularly for prolonged SE with repeated failures to wean off of anesthetic dose drips or for intermittent NCSE. These medications may be helpful for preventing breakthrough and withdrawal seizures, particularly just prior to tapering continuous IV AEDs. Some preliminary evidence shows that topiramate (Niebauer and Gruenthal, 1999) and levetiracetam (Klitgaard, 2001) may have neuroprotective or antiepileptogenic properties as well. Levetiracetam has recently become available in an IV formulation; although not USFDA approved for use in SE, it is being tested in clinical trials and results should be available soon. It is currently approved for up to 1500 mg IV given over 15 minutes as replacement for oral dosing (1:1 ratio), but data show safety and tolerability in normal volunteers at higher and faster rates of up to 2500 mg in 5 minutes or 4000 mg over 15 minutes (Ramael et al, 2006) .
Facilitating early treatment-the role of alternative modes of administering treatment for SE and seizure clusters (not IV or oral Time, Minutes Action 0-5 Diagnose; give oxygen; stabilize airway, breathing, and circulation; obtain IV access; begin EKG monitoring; draw blood for Chem-7, magnesium, calcium, phosphate, complete blood count, liver function tests, antiepileptic drug levels, arterial blood gas, troponin; toxicology screen (urine and blood).
6-10
Thiamine 100 mg IV; 50 mL of 50% dextrose IV unless adequate glucose known. >60 minutes CIV pentobarbital. Load: 5 mg/kg at up to 50 mg/min; repeat 5 mg/kg boluses until seizures stop. Initial CIV rate: 1 mg/kg/h. CIV dose range: 0.5 mg/kg/h to 10 mg/kg/h; traditionally titrated to suppression burst on EEG but titrating to seizure suppression is reasonable as well.
Begin EEG monitoring as soon as possible if patient does not rapidly awaken or if any CIV treatment is used.
The IV solution of diazepam can be given rectally if Diastat is not available; the IV solution of midazolam can be given by any of these routes. b Prolonged use of propofol at >5 mg/kg/h increases the risk of the propofol infusion syndrome; see text.
21% with placebo). Importantly, the rate of respiratory depression or circulatory complications was lower in the two benzodiazepine groups (10.0% to 11.0%) compared with the placebo group (22.5%). This and other studies confirm that not giving benzodiazepines is riskier than giving them for prolonged convulsive seizures. If widely practiced (as is occurring in many countries), this type of rapid prehospital treatment could have a major impact on the prevention of refractory SE. Investigated alternative modes of administration (primarily of benzodiazepines, especially midazolam) include buccal, intranasal, IM, and rectal. Good efficacy and rapid seizure control have been demonstrated for all of these routes (Lahat et al, 2000; Scott et al, 1999) . Currently, the only USFDAapproved and commonly used version of these options is a rectal diazepam gel (Diastat, Xcel Pharmaceuticals, San Diego, CA) available in prefilled syringes. However, buccal or intranasal benzodiazepines (primarily midazolam) are easier to administer and more socially acceptable than the rectal route and allow patients to treat themselves during prolonged auras, simple partial seizures, or clusters with recovery between seizures. Several prospective, randomized studies have shown that buccal or nasal midazolam is equal or superior to IV or rectal benzodiazepines, primarily because of the more rapid administration (Baysun et al, 2005; McIntyre et al, 2005; Scott et al, 1999) . Thus, buccal or nasal midazolam-or another rapid-acting benzodiazepineshould become the outpatient treatment of choice as soon as a practical form becomes widely available; a buccal midazolam preparation is already available in several countries, but not in the United States. The midazolam dose is usually 0.2 mg/kg to 0.3 mg/kg IM/intranasal/buccally, or 10 mg in an adult. 
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B. IV Phenytoin
Overview Phenytoin is the most commonly used second-line therapy in SE. It inhibits high-frequency repetitive firing by blocking voltage-dependent sodium channels.
Loading Dose 20 mg/kg IV, maximum infusion rate 50 mg/min.
Onset of Action 20 to 25 Minutes.
Contraindications
Heart block, caution if impaired liver and renal function.
Main Drug Interactions
Highly protein bound (>90%), may displace other drugs that are also protein bound and increase free levels of other drugs. Also induces hepatic metabolism of many medications, including other AEDs.
Main Side Effects
Cardiac arrhythmias (bradycardia, ectopic beats), hypotension, hepatotoxicity, pancytopenia, phlebitis, soft tissue injury from extravasation, purple glove syndrome, allergy including Stevens-Johnson syndrome.
Target Serum Levels During and after SE, target free phenytoin level 2.0 g/mL to 2.5 g/mL, equivalent to a total phenytoin level of 20 g/mL to 25 g/mL in the presence of normal protein binding. Daily serum levels should be followed. Free phenytoin levels (the active, unbound portion) can become very high in patients with low albumin (malnutrition, critical illness, liver insufficiency) or those who are on other highly protein-bound drugs such as benzodiazepines and valproate.
Comments
It cannot be mixed with glucose/dextrose due to precipitation, cannot be given IM, and should not be given in small peripheral veins.
C. IV Fosphenytoin
Overview Fosphenytoin is a phenytoin prodrug without the propylene glycol carrier and has fewer side effects. It is quickly dephosphorylated to phenytoin when given IM or IV. IV fosphenytoin is preferred to IV phenytoin because of its water solubility and normal pH, allowing more rapid administration with less irritation of veins, less hypotension during administration, no risk of skin necrosis or purple glove syndrome with extravasation, and compatibility with all IV fluids. It is dosed as phenytoin equivalents.
continued on next page
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Loading Dose 20 mg/kg IV, maximum infusion rate 150 mg/min (3 times the rate of phenytoin). If patients continue to have seizures after 20 mg/kg, an additional 5 mg/kg to 10 mg/kg may be given.
Elimination Half-life 10 to 15 Minutes for conversion to phenytoin; then same as phenytoin.
Main Side Effects
Less hypotension than phenytoin (5% to 15%, rate dependent), rare arrhythmias, rare respiratory depression or decreased consciousness, transient pruritus (in up to 50% of awake patients is not an allergic reaction and does not require stopping the drug; often in the groin; possibly due to phosphate load). Cardiac complications can still occur with fosphenytoin; monitor blood pressure and EKG well after infusion ends since phenytoin is effectively still being loaded for more than 15 minutes after the end of the infusion. Otherwise side effects are the same as phenytoin.
Target Serum Levels See phenytoin. Serum phenytoin levels should be obtained >2 hours after an IV load or >4 hours after IM to allow complete conversion to phenytoin.
D. IV Valproate
Overview Although currently not approved by the US Food and Drug Administration for use in SE, several small case series suggest good efficacy for IV valproate in the treatment of different types of SE, including partial onset, nonconvulsive, absence, and myoclonic status (Limdi et al, 2005; Sinha and Naritoku, 2000) .
Loading Dose 20 mg/kg IV; however, for urgent treatment of seizures, higher doses of 30 mg/kg to 60 mg/kg are often needed. Maximum bolus rate: approved for rates up to 3 mg/kg/min for a total loading dose of up to 15 mg/kg (although we and others give much larger loading doses as above). Faster rates have been well tolerated, including 5 mg/kg/min to 6 mg/kg/min (Limdi and Faught, 2000; Wheless et al, 2004) .
Contraindications
Severe liver dysfunction, thrombocytopenia, active bleeding.
Major Drug Interactions
Due to interaction between phenytoin and valproic acid, both heavily protein-bound AEDs, it is important to follow unbound (free) levels, especially of phenytoin, to avoid toxicity. In combination with phenobarbital, valproate can cause severe impaired mental status. Meropenem (and probably other carbapenem antibiotics) decreases valproate concentrations dramatically (Fudio et al, 2006) .
Main Side Effects
Hepatotoxicity (including fatal), thrombocytopenia, pancreatitis; hypotension is very rare but has been reported (White et al, 1999), hyperammonemic encephalopathy.
Target Serum Levels 70 to 140 g/mL for SE.
Comments
Minimal sedation (intubation may be avoided); thus, it is particularly useful for refractory SE in a patient who has ''do not intubate'' status.
E. IV Phenobarbital
Overview A long-acting barbiturate that acts by potentiation of GABA and by interfering with sodium and potassium transport across the cell membrane.
Loading Dose 15 mg/kg to 20 mg/kg IV, maximum infusion rate 50 mg/min to 100 mg/min.
Elimination Half-life 72 Hours.
Contraindications
Severe liver dysfunction. 
G. Continuous IV Midazolam Infusion
Loading Dose 0.2 mg/kg. Repeat 0.2 mg/kg to 0.4 mg/kg boluses every 5 minutes until seizures stop, up to a maximum total loading dose of 2 mg/kg.
Continuous IV Dose Range
Initial infusion rate: 0.1 mg/kg/h. Usual maintenance range 0.05 mg/kg/h to 2.9 mg/kg/h (this is higher than in older literature). For breakthrough seizures, an additional bolus can be given, and the continuous IV rate should be increased by approximately 20%.
Time to Stop Status Epilepticus
Minutes; usually less than 1 hour.
Duration of Antiepileptic Effects
Minutes to hours.
Elimination Half-life 1.5 to 3.5 Hours initially. With prolonged use, tolerance, tachyphylaxis, and significant prolongation of half-life up to days may occur (Naritoku and Sinha, 2000).
Main Side Effects
Sedation of minutes to several hours and possibly days if prolonged use, respiratory depression, hypotension.
H. Continuous IV Propofol Infusion
Overview Propofol is a GABA A agonist, and suppresses seizure activity via GABAmediated inhibition of neuronal firing. Other mechanisms of action include inhibition of the NMDA receptor and modulation of calcium influx through slow calcium ion channels.
Loading Dose 1 mg/kg. Repeat 1 mg/kg to 2 mg/kg boluses every 3 to 5 minutes until seizures stop, up to maximum loading dose of 10 mg/kg. Initial continuous IV rate: 2 mg/kg/h. 
Pediatric Perspective
Convulsive SE is the most common medical neurologic emergency in childhood (DeLorenzo et al, 1995) . Etiology of SE in children differs from that of adults, with prolonged febrile seizures being the most common cause of SE; this is generally associated with low morbidity and mortality (Chin et al, 2006; Hesdorffer et al, 1998) . Other etiologies are listed in Figure 6 -11. In fact, the distribution of etiology has been reported to be highly age dependent. Acute
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Continuous IV Dose Range 1 mg/kg/h to 15 mg/kg/h. Do not exceed >5 mg/kg/h for >48 hours due to risk of propofol infusion syndrome.
Time to Stop Status Epilepticus
Usually <10 minutes.
Contraindications
Allergy to soybean oil, egg lecithin, or glycerol; use with caution in combination with carbonic anhydrase inhibitors, including zonisamide and topiramate, due to risk of refractory acidosis.
Main Side Effects
Sedation; large lipid load (3000 cal/d) requiring adjustment of caloric intake; occasional pancreatitis; dose-dependent hypotension; potentially fatal multiorgan failure, and the propofol infusion syndrome (metabolic acidosis, rhabdomyolysis, and circulatory collapse) with high dose or prolonged use, especially in children (Hanna and Ramundo, 1998) . Follow acid-base status, creatine phosphokinase, triglycerides, and cardiovascular status closely if using high doses (>5 mg/kg/h) or for a prolonged time.
Comments
The use of propofol in adults at doses of 2.1 mg/kg/h to 13.0 mg/kg/h for under 2 weeks with close monitoring including acid/base status appears to be safe and effective based on recent data (Rossetti et al, 2004) and from the experience of many centers anecdotally. It may also be used safely in children with careful dosing and monitoring (van Gestel et al, 2005) .
I. Continuous IV Pentobarbital Infusion
Loading Dose 5 mg/kg. Repeat 5 mg/kg boluses until seizures stop. Maximum bolus rate: 25 mg/min to 50 mg/min (based on blood pressure).
Continuous IV Dose Range
Initial infusion rate 1 mg/kg/h. Usual maintenance range 0.5 mg/kg/h to 10.0 mg/kg/h, traditionally titrated to suppression burst on EEG.
Elimination Half-life 15 to 60 Hours. , 1997) .
Main Side Effects
The general principles of management and the initial agents used in the pediatric population remain the same as adults (Table 6-4) . The initial drug of choice is IV lorazepam when an IV is available, at 0.05 mg/kg to 0.10 mg/kg, and it may be repeated once after 5 minutes if necessary (Eriksson and Kalviainen, 2005) . If IV access cannot be established or the child is in an outof-hospital setting, rectal diazepam at 0.2 mg/kg to 0.5 mg/kg should be given, or nasal/buccal benzodiazepines as just discussed. IV propofol may be a poor option in children, in contrast to adults, because of the risk of multiorgan failure and the propofol infusion syndrome (Table 6-6H) (Hanna and Ramundo, 1998), although proper dosing may allow safe use in a pediatric population (van Gestel et al, 2005) . IV VPA should be used cautiously, if at all, in children under age 2 or children with metabolic disorders at any age because of the risk of fatal hepatotoxicity.
Refractory Status Epilepticus
Most authors define refractory SE (RSE) as generalized convulsive or nonconvulsive SE that continues clinically or electrographically despite first-and second-line therapy. The failure to treat aggressively early on increases the likelihood of developing RSE. After failure of benzodiazepines and phenytoin/fosphenytoin, the traditional treatment algorithm suggests loading with phenobarbital, followed by continuous IV pentobarbital if that fails. We, and others, usually choose to proceed directly to rapid-acting, highly potent drips (midazolam or propofol) once a patient has failed first-(and possibly second-) line drugs rather than to phenobarbital.
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FIGURE 6-11 Causes of first-ever episodes of convulsive status epilepticus in children. PFS = prolonged febrile seizure; acute = acute symptomatic; ABM = acute bacterial meningitis; viral CNS = acute viral CNS infection, acute metabolic = acute metabolic disturbance; CVA = cerebrovascular accident; remote = remote symptomatic; acute on remote = acute on remote symptomatic; idiopathic = idiopathic epilepsy related; cryptogenic = cryptogenic epilepsy related. A IV valproate should be used cautiously, if at all, in children under age 2 or children with metabolic disorders at any age because of the risk of fatal hepatotoxicity.
KEY POINTS:
A Continuous IV propofol may be a poor option in children due to the risk of multiorgan failure and the propofol infusion syndrome, although proper dosing may allow safe use.
A Pruritus during fosphenytoin infusion is not an allergic reaction and does not require stopping the drug (although slowing the rate may decrease itching). It is most likely due to the phosphate load.
In a systematic review of the literature on treatment of RSE, Claassen and colleagues found no difference in mortality (48%) comparing 193 RSE patients treated with continuous IV propofol, continuous IV midazolam, or continuous IV pentobarbital (Claassen et al, 2002a) . This review also demonstrated no differences between propofol and midazolam for clinical end points such as acute treatment failure, breakthrough seizures, or posttreatment seizures. By contrast, pentobarbital had a lower frequency of acute treatment failure and breakthrough seizures. Because the vast majority of patients treated with a goal of EEG background suppression were given pentobarbital (79 of 87), it is difficult to determine whether pentobarbital or the titration goal per se might be responsible for the improved treatment response observed in the pentobarbital group. Another major limitation of this study was the fact that compared with those treated with midazolam or propofol, significantly fewer pentobarbitaltreated patients underwent continuous EEG monitoring. This discrepancy may very likely explain the lower frequency short-term treatment failure and breakthrough seizures found in pentobarbital-treated patients. In our experience and others (Claassen et al, 2001; DeLorenzo et al, 1998) , most breakthrough seizures in these patients are subclinical (89% in our midazolam series [Claassen et al, 2001 ]) and will be unnoticed without continuous EEG monitoring. Hypotension also occurred more often with pentobarbital (titrated to EEG background suppression) than with propofol or midazolam (usually titrated to suppression of seizures) (Claassen et al, 2002a) .
A recent series published after the Claassen systematic review showed good results with propofol combined with IV clonazepam infusion (Rossetti et al, 2004) : 67% of 31 episodes of SE were successfully treated, with no major drug-related adverse events and a favorable mortality rate of only 22%. Their mean propofol infusion rate was 4.8 mg/kg/h (range 2.1 mg/kg/h to 13.0 mg/kg/h, with a goal to achieve burst suppression), and the median duration of treatment was 3 days (range 1 to 9). It may be that concomitant IV benzodiazepines allowed use of a lower and safer dose of propofol-ie, the benzodiazepine infusion was used as a propofol ''dose-sparing'' technique. Other treatments that have been used for RSE include very high-dose phenobarbital (primarily in children, with serum levels 100 mg/mL to 300 mg/ mL); thiopental, lorazepam, and diazepam as continuous infusions; lidocaine, etomidate, isoflurane, and other inhalational anesthetics; paraldehyde; electroconvulsive therapy; transcranial magnetic stimulation; and neurosurgery. See Robakis and Hirsch (2006) for a detailed discussion of treatment of prolonged highly RSE.
Tapering off continuous infusions. In all patients treated with continuous infusions of an AED, the effective dose should be continued for 12 to 24 hours after seizures are stopped before a gradual taper is started. Our practice is to taper off continuous infusions over approximately 24 hours. If seizures recurred with a prior taper, it may be necessary to treat longer and taper more slowly the next time while maintaining high therapeutic levels of other AEDs. Maintaining patients on phenobarbital may increase the chances of weaning off of pentobarbital without seizure recurrence (Krishnamurthy and Drislane, 1996) .
How aggressively should one treat? No studies have demonstrated a convincing difference in outcome based on the goal of treatment (seizure suppression versus burst suppression versus flatline) independent of etiology. In the most recent attempt to answer this question, Rossetti and Bromfield (2005) reviewed 49 episodes of refractory SE and concluded that outcome was independent of the agent of choice and the extent of EEG suppression. Similarly, how aggressively to treat nonconvulsive SE continues to be a subject of debate (Jordan and Hirsch, 2006) .
OUTCOME AND PROGNOSIS

Mortality
Mortality in SE has been reported to be 17% to 23% (Claassen et al, 2002b; Logroscino et al, 2001) . Important predictors of mortality include old age, acute symptomatic etiology, impairment of consciousness, and duration of SE (Claassen et al, 2002b; Logroscino et al, 2001; Lowenstein and Alldredge, 1998; Rossetti et al, 2006; Young et al, 1996) . In a study of NCSE in ICU patients, seizure duration was the single major predictor of mortality on multivariate analysis: if duration was less than 10 hours, 60% returned home and 10% died; if duration was greater than 20 hours, none returned home and 85% died (Young et al, 1996) .
Morbidity
Using a variety of definitions, prior studies indicate that approximately 10% to 23% of patients who survive SE are left with disabling neurologic deficits (Claassen et al, 2002b; Lowenstein and Alldredge, 1998) . Predictors of disability were acute symptomatic seizures and length of hospitalization. EEG findings of NCSE, ictal discharges, and periodic discharges have been associated with poor outcome and mortality after generalized convulsive SE, even after controlling for etiology (DeLorenzo et al, 1998; Jaitly et al, 1997; Nei et al, 1999) .
Nonconvulsive Status Epilepticus
Data seem conflicting on the morbidity and mortality associated with NCSE, but this is primarily because of the fact that NCSE includes two quite distinct groups: the ''wandering confused'' presenting to the emergency department, who have a good prognosis, and the acutely ill stuporous or comatose patients, who have a much poorer prognosis. Several studies have found worse outcome with NCSE in the setting of acute brain disease, severe mental status impairment, and longer seizure duration (Claassen et al, 2001; DeLorenzo et al, 1998; Shneker and Fountain, 2003; Young et al, 1996) . Shneker and Fountain (2003) recently reported outcomes in a series of 100 patients in NCSE: 18% of patients died. Worse outcome was seen in patients with an acute medical (systemic or neurologic) cause of NCSE (27% mortality), as compared with those without an acute medical cause (3%). Patients with severe mental status impairment had a mortality rate of 39% (Shneker and Fountain, 2003) .
Refractory Status Epilepticus
Outcome in RSE is poor: mortality is almost 50%, and only a minority of patients return to their premorbid functional baseline, primarily those with preexisting epilepsy and no acute brain process (Claassen et al, 2001; Claassen et al, 2002b; Mayer et al, 2002) . Similar to SE in general, mortality in RSE is associated with older age, etiology (especially anoxic injury and subarachnoid hemorrhage), long seizure duration, and high Acute Physiology and Chronic Health Evaluation-2 (APACHE-2) scale scores (Claassen et al, 2002b; Towne et al, 1994; Young et al, 1996) . after control of clinical SE, as a substantial proportion of patients (14% to 20%) will still be experiencing electrographic seizures. This can also occur after single brief convulsions (Tay et al, 2006 ) (Case 6-2). In the study by DeLorenzo and colleagues (1998), 14% of patients treated successfully (seemingly) for convulsive SE were in NCSE when EEG was begun; of the patients who underwent continuous EEG monitoring after convulsive SE was controlled, 48% had nonconvulsive seizures on monitoring. Furthermore, once treatment for SE has begun, especially with continuous infusions, the vast majority (approximately 90%) of breakthrough seizures will be subclinical.
EEG in Status Epilepticus
EEG findings in the aftermath of SE include a range of periodic epileptiform discharges (PEDs) that do not meet formal seizure criteria. PEDs are characterized by a spike, sharp wave, or sharply contoured slow wave, usually followed by a slow wave that recurs every 1 to 2 seconds on average. These may be generalized (GPEDs) ( Figure  6-12) , lateralized (Figure 6-13) , or bilateral but independent. These controversial EEG findings in the setting of SE may be considered on an ictal/interictal continuum since they do not meet formal seizure criteria and their exact nature and significance are poorly understood. Husain and colleagues (1999) attempted to shed light on this issue by carefully studying GPEDs in patients with and without SE. Although there were some distinguishing features in grouped data (longer GPED duration, higher GPED amplitude, and higher inter-GPED amplitude in patients with SE compared with those who were not in SE) the authors concluded (and we agree) that ''no generalizations regarding etiology, treatment, and prognosis can be made when GPEDs are seen on an EEG.'' Whether patients benefit from treatment of these EEG findings (including intermittent, brief nonconvulsive seizures) is currently unknown. In fact, one retrospective study suggests that aggressive ICU management of NCSE in elderly, critically ill patients is harmful rather than beneficial (Litt et al, 1998) . For additional discussion on which EEG patterns require treatment, albeit without many definitive conclusions possible, see Chong and Hirsch (2005) .
FUTURE DIRECTIONS
Although IV lorazepam is an excellent and proven first-line treatment for convulsive SE, the steps after this are less clear and require randomized trials. Additional randomized trials are clearly needed to help decide which agents to use and the goal or depth of treatment: cessation of seizures versus suppression of background. Neuroprotection will probably be the next important focus for research. Preliminary evidence suggests that some of the newer AEDs have neuroprotective and antiepileptogenic properties (ie, they may prevent neuronal injury and/ or future epilepsy). Other potential neuroprotective agents or methods that may be worthy of study in SE include hypothermia, glutamate receptor antagonists, calcium channel blockers, antioxidants, and erythropoietin.
Development of a reliable neuronal injury marker will be quite helpful in determining which patients and EEG patterns require treatment and may serve as a surrogate marker for outcome. The preliminary work of DeGiorgio and colleagues (1999) and others suggests that neuron-specific enolase may be an appropriate marker for this. After single seizures, neuron-specific enolase is usually normal or elevated for a few hours only. However, after SE, it is often elevated for days. Neuronspecific enolase correlates with the duration of SE and the outcome. It is most elevated in patients with subtle or nonconvulsive seizures. It is also elevated in patients with SE but without any acute brain injury, further suggesting that seizures themselves, including 143 FIGURE 6-13 Right hemisphere periodic lateralized epileptiform discharge. nonconvulsive ones, can cause neuronal injury.
Education about the prevalence of subclinical seizures and NCSE is of great importance. Nonconvulsive seizures have been reported in 34% of neurologic ICU patients (Jordan, 1999) , 16% of patients with severe head trauma (Vespa et al, 1999) , and 8% of comatose patients who have no clinical evidence of seizures (Towne et al, 2000) . Diagnosis is often delayed, and this delay has been found to correlate with a worse prognosis (Young et al, 1996) . Education and training regarding the pitfalls of EEG interpretation will also be important. It is critical not to misinterpret artifact or encephalopathic patterns as ictal, admittedly not always an easy task; review of simultaneous video is quite helpful in this regard.
Whether further brain injury is occurring during NCSE or periodic discharges can be studied in many ways, perhaps most effectively with animal models. In humans, many potential markers of neuronal injury are now available. In addition, a variety of noninvasive methods of studying the underlying pathophysiology during and after SE exist. These include MRI with diffusion-weighted imaging (often shows focal bright signal during and after SE), fMRI, serum and CSF markers such as neuron-specific enolase discussed above, PET, SPECT, and magnetic resonance spectroscopy (eg, for lactate). Other more invasive monitoring techniques such as brain tissue oxygen and cerebral microdialysis (for parenchymal interstitial fluid lactate, pyruvate, glutamate, glycerol, neurotransmitters, and more) can be employed. Hopefully all these techniques, combined with clinical trials and experience, will enable more definitive evidence-based recommendations and improved outcomes in management of patients with SE. This randomized double-blinded study confirmed that benzodiazepines can be used safely in out-of-hospital settings (safer than placebo) and that IV lorazepam was superior to diazepam and placebo. Large population-based study reporting a higher incidence of convulsive SE in childhood with a range of causes, and a lower risk of death compared to adults. This comprehensive review suggests that treatment with pentobarbital, or perhaps any continuous IV antiepileptic drug (AED) infusion to attain EEG background suppression, may be a more effective treatment for refractory SE, but at the expense of greater side effects and no difference in ultimate outcome. This survey found lorazepam to be the most commonly used treatment for SE, followed by phenytoin or fosphenytoin as first-line and second-line therapies for generalized convulsive SE. This retrospective study found older age, the presence of acute symptomatic seizures, and longer hospital stay to be independent predictors of a worse prognosis in SE. This study of 570 patients illustrates the importance of continuous EEG monitoring in detecting nonconvulsive seizures and nonconvulsive status epilepticus (NCSE) in the ICU setting, especially in comatose patients. More than 90% of the seizures that were recorded were nonconvulsive and would have been missed without EEG monitoring. Preliminary study suggesting an important role for neuron-specific enolase as a neuronal injury marker. A prospective, population-based study documenting the incidence and mortality associated with SE. The results of this retrospective study suggested that etiology may help predict the initial response to treatment as well as short-term outcome in patients with SE. Also, first-line medications control SE in 80% of patients when initiated within 30 minutes, but in only 40% if started after 2 hours of onset. The authors propose a revision of the traditional definition of SE (seizure activity persisting for at least 30 minutes) to a cutoff of 10 minutes, since there is evidence that very few seizures last more than 5 minutes. A retrospective study that reported an association of refractory SE with NCSE and focal motor seizures at the onset. In this study, animal data are presented, supporting the concept that pharmacologic therapeutic interventions are most effective when initiated early and that efficacy decreases significantly with increasing seizure duration. A pilot study of 68 patients with SE, documenting superior efficacy of IV valproate (66%) compared with IV phenytoin (42%) as first-line treatment; tolerability between the two groups did not differ. This study found an association between occurrence of periodic discharges on EEG and worse outcome. This study showed that seizures in patients with intracerebral hemorrhage are associated with increased midline shift independent of the size of hemorrhage. This analysis highlighted the risk factors, primarily seizure duration and delay to diagnosis, that are associated with high mortality in NCSE.
